Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde

Respirology

Volumn 19, Issue 1, 2014, Pages 74-79

  Antus, Balazs ^a   Harnasi, Gabriella ^a   Drozdovszky, Orsolya ^a   Barta, Imre ^a  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

Author keywords

chronic obstructive pulmonary disease; exhaled breath condensate; oxidative stress; repeatability; sputum

Indexed keywords

MALONALDEHYDE; POLYUNSATURATED FATTY ACID;

ADULT; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EXHALED BREATH CONDENSATE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LIPID PEROXIDATION; LONGITUDINAL STUDY; LUNG FUNCTION; MALE; MEASUREMENT REPEATABILITY; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; SMOKING; SPUTUM ANALYSIS;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EXHALED BREATH CONDENSATE; OXIDATIVE STRESS; REPEATABILITY; SPUTUM;

BIOLOGICAL MARKERS; BREATH TESTS; DISEASE PROGRESSION; EXHALATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPUTUM;

EID: 84896510795     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12155     Document Type: Article

References (20)

1. Tuder RM, Petrache I,. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 2012; 122: 2749-2755.
2. Rahman I, Adcock IM,. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 2006; 28: 219-242.
3. Bathoorn E, Kerstjens H, Postma D, et al. Airways inflammation and treatment during acute exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 217-229.
4. Rahman I, Biswas SK,. Non-invasive biomarkers of oxidative stress: reproducibility and methodological issues. Redox. Rep. 2004; 9: 125-143.
5. Hillas G, Loukides S, Kostikas K, et al. Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect? Curr. Med. Chem. 2009; 16: 2824-2838.
6. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 6-14.
7. Lärstad M, Ljungkvist G, Olin AC, et al. Determination of malondialdehyde in breath condensate by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002; 766: 107-114.
8. Corradi M, Rubinstein I, Andreoli R, et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1380-1386.
9. Bartoli ML, Novelli F, Costa F, et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm. 2011; 891752 1-7.
10. Corradi M, Pignatti P, Manini P, et al. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur. Respir. J. 2004; 24: 1011-1017.
11. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-555.
12. Antus B, Barta I, Kullmann T, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. Am. J. Respir. Crit. Care Med. 2010; 182: 1492-1497.
13. Antus B, Barta I, Csiszer E, et al. Exhaled breath condensate pH in patients with cystic fibrosis. Inflamm. Res. 2012; 61: 1141-1147.
14. Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
15. Corradi M, Folesani G, Andreoli R, et al. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am. J. Respir. Crit. Care Med. 2003; 167: 395-399.
16. Franklin P, Moeller A, Hall GL, et al. Variability of nitric oxide metabolites in exhaled breath condensate. Respir. Med. 2006; 100: 123-129.
17. Borrill ZL, Starkey RC, Singh SD,. Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2007; 2: 71-76.
18. Kullmann T, Barta I, Antus B, et al. Drinking influences exhaled breath condensate acidity. Lung 2008; 186: 263-268.
19. Giera M, Lingeman H, Niessen WM,. Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): a brief overview. Chromatographia 2012; 75: 433-440.
20. Bathoorn E, Liesker J, Postma D, et al. Safety of sputum induction during exacerbations of COPD. Chest 2007; 131: 432-438.